Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on June 8, 2009, reporting events occurring on June 5, 2009. The filing details the closing of a registered direct offering of common stock and warrants previously announced on May 20, 2009.
Key Financial Metrics
- Gross Proceeds: $3 million in cash.
- Shares Issued: 2,857,143 shares of common stock at $1.05 per share.
- Warrants Issued: Warrants to purchase 5,644,443 shares of common stock with an aggregate exercise price of $7 million.
- Shares Outstanding: 60,716,133 shares following the offering.
- Placement Agent: Rodman & Renshaw, LLC.
The filing does not provide data on revenue, profit, operating cash flow, margins, debt, or liquidity ratios.
Material Changes
The primary material change is the increase in share count and capitalization resulting from the closing of the equity offering. The company's outstanding share count increased to 60,716,133 shares post-closing.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of the transaction closing. The filing incorporates by reference a press release dated June 5, 2009 (Exhibit 99.1) for further details. No specific guidance, risk factors, or contingencies are detailed within the text of this specific 8-K form.
Investor Verification Checklist
- Verify the final use of the $3 million gross proceeds as disclosed in the incorporated press release.
- Confirm the specific terms and expiration dates of the warrants issued to the institutional investor.
- Review the impact of the 2,857,143 new shares on existing shareholder dilution.
- Check for any underwriting discounts or commissions paid to Rodman & Renshaw, LLC that may reduce net proceeds.